Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals

NCT04703075 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.

NCT NCT04703075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04703075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals
Lead sponsor
Johns Hopkins University
Phase
Phase 4
Overall status
Completed
Start date
March 24, 2022
Completion date
June 10, 2024
Enrollment
531 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis